NKCx Histopathological outcome* within 12 months after cervix cytology in 2018 |
411 Lund |
Benign | CIN1 | CIN2 | CIN3 | AIS | Cancer | Other | PAD missing | Total | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytology | Count | Pct | Count | Pct | Count | Pct | Count | Pct | Antal | Andel | Count | Pct | Count | Pct | Count | Pct | Count | Pct |
Benign sample | 150 | 0.7% | 9 | 0.0% | 1 | 0.0% | 1 | 0.0% | . | . | 3 | 0.0% | 1 | 0.0% | 21165 | 99.2% | 21330 | 100.0% |
ASCUS | 469 | 26.5% | 190 | 10.7% | . | . | 65 | 3.7% | 2 | 0.1% | 2 | 0.1% | 24 | 1.4% | 1021 | 57.6% | 1773 | 100.0% |
CIN1 | 307 | 23.6% | 237 | 18.2% | 1 | 0.1% | 116 | 8.9% | 2 | 0.2% | . | . | 26 | 2.0% | 612 | 47.0% | 1301 | 100.0% |
Atypical glandular cells/AGC | 8 | 38.1% | 1 | 4.8% | . | . | 3 | 14.3% | 2 | 9.5% | 3 | 14.3% | . | . | 4 | 19.0% | 21 | 100.0% |
Unclear atypia | 3 | 33.3% | 3 | 33.3% | . | . | 1 | 11.1% | 1 | 11.1% | 1 | 11.1% | . | . | . | . | 9 | 100.0% |
ASC-H | 39 | 15.5% | 44 | 17.5% | . | . | 137 | 54.4% | 5 | 2.0% | . | . | 3 | 1.2% | 24 | 9.5% | 252 | 100.0% |
CIN3 | 25 | 6.3% | 29 | 7.3% | 1 | 0.3% | 292 | 73.0% | 10 | 2.5% | 15 | 3.8% | 1 | 0.3% | 27 | 6.8% | 400 | 100.0% |
Adenocarcinoma | 1 | 5.6% | . | . | . | . | . | . | 12 | 66.7% | 1 | 5.6% | 2 | 11.1% | 2 | 11.1% | 18 | 100.0% |
Malignant tumor with unclear origin | . | . | . | . | . | . | . | . | . | . | . | . | . | . | 1 | 100.0% | 1 | 100.0% |
Squamous cell cancer | . | . | . | . | . | . | 1 | 14.3% | . | . | 3 | 42.9% | . | . | 3 | 42.9% | 7 | 100.0% |
Total | 1002 | 4.0% | 513 | 2.0% | 3 | 0.0% | 616 | 2.5% | 34 | 0.1% | 28 | 0.1% | 57 | 0.2% | 22859 | 91.0% | 25112 | 100.0% |
NOTE: Histopathological outcome from T83x taken into account. |
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
Process Registry's Class 1 (benign), 2d (CIN1) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
Snomed codes in the category Cancer: |
---|
M80009, M80413, M80703, M81401, M81403, M83803 |